Literature DB >> 17072806

[Costs deriving from strokes from a social perspective. A retrospective incidence approach with a follow-up at three years].

A Hervás-Angulo1, J M Cabasés-Hita, T Forcén-Alonso.   

Abstract

INTRODUCTION: The costs deriving from strokes are important from a social point of view because this is a pathology with a substantial individual, familial and social impact. Cost-of-illness studies provide an overall description of the economic aspects of strokes. The widest perspective is the social one, where all the costs and consequences are included. If possible, it is wise to take a bottom-up approach. AIMS: To calculate the costs deriving from strokes from the social perspective in the population of a district health service (12,000 inhabitants) by means of a retrospective incidence approach (follow-up at three years) and a bottom-up procedure. We also intended to calculate the fractions that can be attributed to primary care, hospital care and social care. PATIENTS AND METHODS: Our study included all the cases of stroke diagnosed between 1st January 1999 and 31st December 2003 within a basic health care district in Navarre (n = 91). DATA COLLECTION: an ad hoc questionnaire -the CACV (cerebrovascular accident cost) questionnaire- which assessed the 'incremental' costs due to strokes and their complications.
RESULTS: The average cost was found to be 5,759.50 euro for the first year, 3,596.60 euro for the second and 4,671.30 euro for the third. The cost in the first year is marked by the hospital care, which accounts for 50% of the total. From the second year onwards the costs of outpatient care become very important, since they represent 70% of the overall costs.
CONCLUSIONS: The costs deriving from strokes in the first three years amount to almost 5,000 euro/year. More cerebrovascular cost-of-illness studies need to be conducted from the social perspective and should therefore include the costs of informal care.

Entities:  

Mesh:

Year:  2006        PMID: 17072806

Source DB:  PubMed          Journal:  Rev Neurol        ISSN: 0210-0010            Impact factor:   0.870


  8 in total

1.  [Ebrictus study. Functional results, survival, and potential years of life lost after the first stroke].

Authors:  J L Clua-Espuny; J L Piñol-Moreso; A Panisello-Tafalla; J Lucas-Noll; V F Gil-Guillen; D Orozco-Beltran; M L Queralt-Tomas
Journal:  Aten Primaria       Date:  2011-09-28       Impact factor: 1.137

2.  Economic impact of patients admitted to stroke units in Spain.

Authors:  Jose Alvarez-Sabín; Manuel Quintana; Jaime Masjuan; Juan Oliva-Moreno; Javier Mar; Nuria Gonzalez-Rojas; Virginia Becerra; Covadonga Torres; María Yebenes
Journal:  Eur J Health Econ       Date:  2016-04-15

Review 3.  Cost of disorders of the brain in Spain.

Authors:  Oleguer Parés-Badell; Gabriela Barbaglia; Petra Jerinic; Anders Gustavsson; Luis Salvador-Carulla; Jordi Alonso
Journal:  PLoS One       Date:  2014-08-18       Impact factor: 3.240

4.  Comparison of Two Post-Stroke Rehabilitation Programs: A Follow-Up Study among Primary versus Specialized Health Care.

Authors:  Remedios López-Liria; Francisco Antonio Vega-Ramírez; Patricia Rocamora-Pérez; José Manuel Aguilar-Parra; David Padilla-Góngora
Journal:  PLoS One       Date:  2016-11-11       Impact factor: 3.240

5.  [Cost-effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type-2 diabetes mellitus in Spain].

Authors:  Eduardo José Abad Paniagua; Pedro Casado Escribano; José María Fernández Rodriguez; Francisco J Morales Escobar; Lourdes Betegón Nicolás; Joaquín Sánchez-Covisa; Max Brosa
Journal:  Aten Primaria       Date:  2014-12-30       Impact factor: 1.137

6.  Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain.

Authors:  Carlos Escobar Cervantes; Julio Martí-Almor; Alejandro Isidoro Pérez Cabeza; Kevin Bowrin; Aleix Llorac Moix; Mar Genís Gironès; David Gasche; Aurélie Millier; Jean Tardu; Mondher Toumi; Jean-Baptiste Briere
Journal:  PLoS One       Date:  2022-04-20       Impact factor: 3.240

7.  Cost-effectiveness analysis of dabigatran and anticoagulation monitoring strategies of vitamin K antagonist.

Authors:  Misericòrdia Carles; Max Brosa; Juan Carlos Souto; Josep Maria Garcia-Alamino; Gordon Guyatt; Pablo Alonso-Coello
Journal:  BMC Health Serv Res       Date:  2015-07-28       Impact factor: 2.655

8.  Economic valuation of informal care in cerebrovascular accident survivors in Spain.

Authors:  Juan Oliva-Moreno; Isaac Aranda-Reneo; Cristina Vilaplana-Prieto; Almudena González-Domínguez; Alvaro Hidalgo-Vega
Journal:  BMC Health Serv Res       Date:  2013-12-05       Impact factor: 2.655

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.